GlassScriptPhysician profile
Caroline D Peeples
NPI 1598328684
$1,723.90
in general payments reported to CMS, 2019-2025
21 companies · $342 in 2025
The $342 reported for 2025 was more than what 78% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
See the full distribution for Women's Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $164 · 2022: $372 · 2023: $526 · 2024: $320 · 2025: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,094 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,093.74 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $268.38 | 2021-2025 | |
| Astellas Pharma US INC | $164.29 | 2023 | Myrbetriq, Veozah |
| Exeltis, USA INC. | $161.88 | 2022-2025 | Slynd |
| Hologic Sales and Service, LLC | $146.17 | 2023-2025 | Novasure, Myosure Tissue Removal Device |
| Organon LLC | $135.15 | 2023-2025 | Nexplanon |
| Pfizer INC. | $122.59 | 2022-2024 | |
| Mayne Pharma Commercial LLC | $117.33 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $110.38 | 2021-2025 | Trintellix |
| Biohaven Pharmaceutical Holding Company LTD. | $102.80 | 2022 | |
| Novo Nordisk INC | $101.65 | 2021-2024 | Saxenda, Wegovy |
| Lilly USA, LLC | $61.89 | 2022-2025 | Zepbound |
| Shield Therapeutics INC | $38.77 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.29 | 2023-2025 | |
| Avion Pharmaceuticals | $32.54 | 2023 | Balcoltra |
| Sumitomo Pharma America, INC. | $29.47 | 2024-2025 | Myfembree, Gemtesa |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $17.90 | 2021 | |
| Currax Pharmaceuticals LLC | $17.86 | 2024 | Contrave, Onzetra Xsail |
| Dexcom, INC. | $17.63 | 2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $14.93 | 2023 | Cologuard Collection Kit |
| Evofem Biosciences, INC. | $13.74 | 2025 | Phexxi, Solosec, Phexx |
| Merck Sharp & Dohme LLC | $11.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Peeples listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.